Institutional Manager · CIK 0001910264
SR One Capital Management, LP
Wayne, PA · File #028-21964
Latest AUM
$706.4M
Positions
13
Top-10 Concentration
97.7%
Filings
9
Portfolio Value Over Time
2024-03
2024-06
2024-09
2024-12
2025-03
2025-06
2025-09
2025-12
Biggest QoQ Changes
Ranked by conviction flow (share change × current price) so mark-to-market moves don't dominate. Price effect column shows how much of the $ change was just the stock moving.
| Action | Issuer | Ticker / CUSIP | Δ Shares | Flow ($) | Price Effect |
|---|---|---|---|---|---|
| REDUCE | Mineralys Therapeutics Inc. | MLYS | -549,967 | -$20.0M | -$3.4M |
| ADD | Oculis Holding AG | OCSAW | +318,522 | +$6.4M | +$770,775 |
| ADD | Zenas BioPharma, Inc | ZBIO | +126,315 | +$4.6M | +$69.3M |
| NEW | Ultragenyx Pharmaceutical Inc. | RARE | +137,753 | +$3.2M | $0 |
| REDUCE | Alumis Inc. | ALMS | 0 | $0 | +$11.3M |
| REDUCE | Arcellx, Inc. | ACLX | 0 | $0 | -$39.7M |
| REDUCE | ARS Pharmaceuticals, Inc. | SPRY | 0 | $0 | +$6.4M |
| REDUCE | CRISPR Therapeutics AG | CRSP | 0 | $0 | -$25.2M |
| REDUCE | Design Therapeutics, Inc. | DSGN | 0 | $0 | +$12.1M |
| REDUCE | enGene Holdings Inc. | ENGNW | 0 | $0 | +$1.6M |
Sector Allocation
Filing History
- 13F HOLDINGS REPORTQ/E Dec 202513 pos · $706.4M
- 13F HOLDINGS REPORTQ/E Sep 202512 pos · $691.4M
- 13F HOLDINGS REPORTQ/E Jun 202513 pos · $461.4M
- 13F HOLDINGS REPORTQ/E Mar 202512 pos · $389.3M
- 13F HOLDINGS REPORTQ/E Dec 202411 pos · $410.1M
- 13F HOLDINGS REPORTQ/E Sep 202411 pos · $498.7M
- 13F HOLDINGS REPORTQ/E Jun 20249 pos · $319.4M
- 13F HOLDINGS REPORTQ/E Mar 20246 pos · $364.1M
- 13F HOLDINGS REPORTQ/E Dec 20236 pos · $195.1M
Top 13 Holdings — Dec 2025
| # | Issuer | Ticker | Shares | Value | % of Portfolio |
|---|---|---|---|---|---|
| 1 | Zenas BioPharma, Inc | ZBIO | 5,037,854 | $182.9M | 25.90% |
| 2 | Arcellx, Inc. | ACLX | 2,346,630 | $153.0M | 21.66% |
| 3 | CRISPR Therapeutics AG | CRSP | 2,038,763 | $106.9M | 15.14% |
| 4 | Design Therapeutics, Inc. | DSGN | 6,526,476 | $61.2M | 8.67% |
| 5 | Mineralys Therapeutics Inc. | MLYS | 1,563,966 | $56.8M | 8.03% |
| 6 | ARS Pharmaceuticals, Inc. | SPRY | 4,012,903 | $46.8M | 6.62% |
| 7 | ORIC Pharmaceuticals, Inc. | ORIC | 4,514,929 | $37.8M | 5.34% |
| 8 | Alumis Inc. | ALMS | 1,959,896 | $19.1M | 2.71% |
| 9 | Oruka Therapeutics, Inc | ORKA | 430,330 | $13.0M | 1.85% |
| 10 | Oculis Holding AG | OCSAW | 641,022 | $12.8M | 1.81% |
| 11 | enGene Holdings Inc. | ENGNW | 747,750 | $6.8M | 0.96% |
| 12 | Nkarta, Inc. | NKTX | 3,333,333 | $6.2M | 0.87% |
| 13 | Ultragenyx Pharmaceutical Inc. | RARE | 137,753 | $3.2M | 0.45% |